Summary
The product Anavar 50mg, manufactured by PharmaQo, underwent independent testing to verify its authenticity and potency. The sample, identified by an unknown batch number, was submitted by the Manufacturer Pharmaqo Labs mrp@vitamins.to and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Oxandrolone, with a concentration of 58.14 mg, which is 116.28% of the labeled claim of 50 mg.
The testing process was conducted on 30 June 2023. The results indicate a significant overdosing, and scrutiny of manufacturer-submitted samples is essential to ensure reliability. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Pharmaqo Labs
- Product Name: Anavar 50mg
- Active Ingredient: Oxandrolone
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #30648
- Testing Ordered: 7 June 2023
- Sample Received: 30 June 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Pharmaqo Labs (Manufacturer)
- Analysis Paid For By: Pharmaqo Labs (Manufacturer)
Testing Results
- Specification: 50 mg (as stated on the label)
- Measured Concentration: 58.14 mg
- Accuracy: 116.28% (16.28% above the label claim)
- Variance: 16.28
Verification Details
Verification URL: https://janoshik.com/tests/30648_E9TR7SZ2JLU5
Evaluation of Manufacturer-Submitted Testing
This analysis highlights a significant overdosing of the tested product and warrants careful evaluation due to its submission by the Manufacturer Pharmaqo Labs. Manufacturer-submitted samples may involve inherent biases, as they might select specific batches that meet high-quality standards. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Anavar 50mg is significantly overdosed, with a measured concentration of 58.14 mg. This result reflects a notable deviation from the labeled claim and underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
